New logo expresses strengthened commitment to greater innovation, growth, and alignment with Saudi Vision 2030 ...

The number of suspected cases of Guillain-Barre Syndrome (GBS) in Maharashtra has surged to 170, with 132 confirmed cases, ...

Management projected strong growth for 2025, driven by expanded reimbursement in key European markets such as Spain and Italy and the expected completion of the post-approval efficacy study (PAES).

The victim, who was hospitalized in Solapur, died late Saturday after a prolonged battle with the rare neurological disorder, ...

Hansa Biopharma AB (HNSBF) reports a robust 35% increase in IDEFIRIX sales and expands its European market presence, despite facing revenue fluctuations and operating losses.

In his new role, he will focus on enhancing the company’s portfolio in critical growth areas, positioning GBS as a key technology enabler in Saudi Arabia. Reflecting on his new leadership appointment, ...

Q4 2024 Earnings Call Transcript February 4, 2025 Gartner, Inc. beats earnings expectations. Reported EPS is $5.45, ...

Hansa Biopharma AB, Hansa or the Company (Nasdaq Stockholm: HNSA) today announced its full year and Q4 2024 financial results. Søren ...

Q3 2025 Earnings Call Transcript February 4, 2025 Operator: Ladies and gentlemen, thank you for standing by. My name is ...

Q3 2025 Earnings Conference Call February 4, 2025 5:00 PM ETCompany ParticipantsRoger Sachs - Vice President and Head ...

One person is believed to have died in India's Maharashtra state in an outbreak of Guillain-Barre syndrome (GBS) - a neurological disease that causes numbness, weakness and pain - and the number of ...